The INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE (CICON): TRANSLATING SCIENCE INTO SURVIVAL was launched in 2015, and today continues to be the most important forum for basic and translational research in cancer immunology and immunotherapy. Presented by the Cancer Research Institute (CRI) and the European Network for Cancer Immunotherapy (ENCI), and alternating between the United States and Europe, CICON is organized by the leaders of this fast-moving field, gathering more than 1,000 cancer immunology and immunotherapy specialists from all over the world.


Cancer Research Institute (CRI), established in 1953, is the preeminent U.S. nonprofit organization dedicated exclusively to saving more lives by fueling the discovery and development of powerful immunotherapies for all cancers. Guided by a world-renowned Scientific Advisory Council that includes four Nobel laureates and 34 members of the National Academy of Sciences, CRI has invested over $517 million in support of research conducted by immunologists and tumor immunologists at the world’s leading medical centers and universities and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment.

The European Network for Cancer Immunotherapy (ENCI) is a collaborative information and networking platform of the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology and the Italian Network for Tumor Biotherapy. ENCI harmonizes the activities of the European cancer immunotherapy community and fosters collaboration across organizations and countries. By providing and disseminating information, organizing scientific meetings and educating political decision makers, ENCI aims to advance the research and implementation of cancer immunotherapy in Europe.

About the ENCI organizations:
The Association for Cancer Immunotherapy (CIMT) is Europe’s largest members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. Founded in 2002, CIMT organizes annual meetings, working groups, advanced education seminars, symposia and publishes white papers, guidelines and textbooks on cancer immunotherapy.

European Academy of Tumor Immunology (EATI) promotes all areas of tumor immunology, considered as a continuum between fundamental, translational and clinical research, as well as the practical implementation of diagnostic and therapeutic procedures in routine clinical practice. Founded in 2010, EATI counts on 199 “Academicians” and more than 1300 members to organize scientific conferences, workshops and seminars, and to publish a dedicated journal, OncoImmunology.

Spanish Group for Cancer Immuno-biotherapy (GÉTICA) is a Spanish non-profit association, working/established in 2014, by and for clinicians and basic or translational researchers interested in tumor immunology and immunotherapies for cancer treatment. GÉTICA’s aims are to promote research and development of novel immunotherapies, to promote education among researchers and clinicians in this field, as well as to endorse public engagement by spreading of cancer immunology and immunotherapy advances/progress. One of GÉTICA’s priorities is to facilitate and integrate other scientific societies and cooperative groups to support a multidisciplinary and collaborative scientific environment and view to boost knowledge in cancer immunology and development of novel immunotherapies.

The Italian Network for Tumor Biotherapy (NIBIT) was established in 2004, to create a cooperative network collecting and coordinating the activities of several Italian groups involved in cancer immunotherapy. The objectives of NIBIT are: (a) to promote and develop scientific, professional and operational interactions between professionals (academy, industry, regulatory agencies) involved in cancer biotherapy; (b) to develop and conduct clinical biotherapy studies, and (c) to inform cancer patients about clinical trials in the network.